Ausgabe 1/2019
Inhalt (32 Artikel)
Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant
Yun Fan, Andrew S. Artz, Koen van Besien, Wendy Stock, Richard A. Larson, Olatoyosi Odenike, Lucy A. Godley, Justin Kline, John M. Cunningham, James L. LaBelle, Michael R. Bishop, Hongtao Liu
Mantle cell lymphoma and its management: where are we now?
Abdullah Ladha, Jianzhi Zhao, Elliot M. Epner, Jeffrey J. Pu
Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia
Pimjai Niparuck, Nittaya Limsuwanachot, Sulada Pukiat, Pichika Chantrathammachart, Budsaba Rerkamnuaychoke, Sutada Magmuang, Sithakom Phusanti, Kochawan Boonyawat, Teeraya Puavilai, Pantep Angchaisuksiri, Artit Ungkanont, Suporn Chuncharunee
Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
N. O’Connor-Byrne, S. Glavey, R. Tudor, P. Murphy, C. J. Thompson, J. Quinn
Immunotherapy in extensive small cell lung cancer
Vaibhav Verma, Geeti Sharma, Abhijai Singh
Thyroid dysfunction from inhibitor of fibroblast growth factor receptor
Jeffrey Ahn, Justin Moyers, John Wong, Chung-Tsen Hsueh
The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016
Mattias Carlsten, Martin Jädersten, Anna Hellström, Karin Littmann, Christopher M. Melén, Henna Riikka Junlén, Kristina Sonnevi, Per Ljungman, Bo Björkstrand, Björn Engelbrekt Wahlin
Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation
Julie Charles, Diane Giovannini, Nicolas Terzi, Carole Schwebel, Nathalie Sturm, Dominique Masson, Marie-Thérèse Leccia, Jean-Yves Cahn, Olivier Manches, Claude-Eric Bulabois, Laurence Chaperot
Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
Stefanie Jilg, Richard T. Hauch, Johanna Kauschinger, Lars Buschhorn, Timo O. Odinius, Veronika Dill, Catharina Müller-Thomas, Tobias Herold, Peter M. Prodinger, Burkhard Schmidt, Dirk Hempel, Florian Bassermann, Christian Peschel, Katharina S. Götze, Ulrike Höckendorf, Torsten Haferlach, Philipp J. Jost
Development of a high resolution melting analysis assay for rapid identification of JAK2 V617F missense mutation and its validation
Alireza Moradabadi, Alireza Farsinejad, Behzad Khansarinejad, Ahamd Fatemi
NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children
Tianyou Yang, Yang Wen, Jiahao Li, Tianbao Tan, Jiliang Yang, Jing Pan, Chao Hu, Yuxiao Yao, Jiao Zhang, Yijuan Xin, Suhong Li, Huimin Xia, Jing He, Yan Zou
Novel GTF2I–PDGFRB and IKZF1–TYW1 fusions in pediatric leukemia with normal karyotype
Ioannis Panagopoulos, Marta Brunetti, Margrethe Stoltenberg, Rønnaug A. U. Strandabø, Julie Staurseth, Kristin Andersen, Ilyá Kostolomov, Tarjei S. Hveem, Susanne Lorenz, Tove Anita Nystad, Trond Flægstad, Francesca Micci, Sverre Heim
An expanded biomarker panel for the detection of prostate cancer from urine DNA
Igor Brikun, Deborah Nusskern, Diha Freije
Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
Ravi Potluri, Sandip Ranjan, Hitesh Bhandari, Helen Johnson, Andriy Moshyk, Srividya Kotapati
Frontline therapies for untreated chronic lymphoid leukemia
Delong Liu, Juanjuan Zhao
Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
Alexandra Albertsson-Lindblad, Catja Freiburghaus, Mats Jerkeman, Sara Ek
Analysis of TET2 mutations in paroxysmal nocturnal hemoglobinuria (PNH)
Camille Lobry, Ashish Bains, Leah B. Zamechek, Sherif Ibrahim, Iannis Aifantis, David J. Araten
A novel RNA variant of human concentrative nucleoside transporter 1 (hCNT1) that is a potential cancer biomarker
Chunmei Wang, John K. Buolamwini
Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
Zhenbin Qiu, Zihao Chen, Chao Zhang, Wenzhao Zhong
Autoimmune rhabdomyolysis and a multiorgan display of PD-1 inhibitor induced immune related adverse events during treatment of metastatic melanoma
Hoda Z. Pourhassan, David Tryon, Brett Schaeffer, Hamid Mirshahidi, John Wong
Role of some members of chemokine/cytokine network in the pathogenesis of thalassemia and sickle cell hemoglobinopathies: a mini review
Zahra Mousavi, Zinat Yazdani, Alireza Moradabadi, Fatemeh Hoseinpourkasgari, Gholamhossein Hassanshahi
Cabozantinib and apixaban: an hitherto unreported interaction
Daniele Santini, Fabrizio Citarella, Bruno Vincenzi, Marco Russano, Giuseppe Tonini, Marco Stellato
LY86, LRG1 and PDE9A genes overexpression in umbilical cord blood hematopoietic stem progenitor cells by acute myeloid leukemia (M3) microvesicles
Farnaz Razmkhah, Sorayya Ghasemi, Masoud Soleimani, Sedigheh Amini Kafi-abad
Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort
Stephen R. Fairclough, Lesli A. Kiedrowski, Jessica J. Lin, Ori Zelichov, Gabi Tarcic, Thomas E. Stinchcombe, Justin I. Odegaard, Richard B. Lanman, Alice T. Shaw, Rebecca J. Nagy
Targeted and novel therapy in advanced gastric cancer
Julie H. Selim, Shagufta Shaheen, Wei-Chun Sheu, Chung-Tsen Hsueh
The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
Kongju Wu, Ming Yi, Shuang Qin, Qian Chu, Xinhua Zheng, Kongming Wu
Development of molecular and pharmacological switches for chimeric antigen receptor T cells
Bill X. Wu, No-Joon Song, Brian P. Riesenberg, Zihai Li
Recent advances on blinatumomab for acute lymphoblastic leukemia
Juanjuan Zhao, Yongping Song, Delong Liu
Advances and perspectives of PARP inhibitors
Ming Yi, Bing Dong, Shuang Qin, Qian Chu, Kongming Wu, Suxia Luo
A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma
Shanshan Zhang, Zhaojian Gong, Peter O. Oladimeji, Duane G. Currier, Qipan Deng, Ming Liu, Taosheng Chen, Yong Li
Gut microbiome and CAR-T therapy
Muhammad Bilal Abid, Nirav N. Shah, Theresa C. Maatman, Parameswaran N. Hari
Immune pressures drive the promoter hypermethylation of neoantigen genes
Ming Yi, Bing Dong, Qian Chu, Kongming Wu